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Background: The Stent-In 2 trial randomized patients with malignant colonic obstruction to emergency
surgery or stent placement as a bridge to elective surgery. The aim of this study was to compare the
oncological outcomes.
Methods: Disease recurrence, and disease-free, disease-specific and overall survival were evaluated,
including a subgroup analysis of patients with a stent- or guidewire-related perforation.
Results: Of 98 patients included in the original Stent-In 2 trial, patients with benign (16) or incurable
(23) disease were excluded from this study, along with a patient who had withdrawn from the trial. Of
the remaining 58 patients, 32 were randomized to emergency surgery (31 resection, 1 stoma only) and
26 to stenting. Unsuccessful stenting required emergency surgery in six patients owing to wire or stent
perforation. Locoregional or distant disease recurrence developed in nine of 32 patients in the emergency
surgery group and 13 of 26 in the stent group. Disease-free survival was worse in the subgroup with stent-
or guidewire-related perforation. Five of six patients in this subgroup developed a recurrence, compared
with nine of 32 in the emergency surgery group and eight of 20 who had unperforated stenting.
Conclusion: Stent placement for malignant colonic obstruction was associated with a risk of recurrence
in this trial, but the numbers are small. There is not enough evidence to refute the approach strongly.
Registration number: ISRCTN46462267 (http://www.controlled-trials.com).
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Introduction
Stenting malignant colonic obstruction as a bridge to
elective surgery has become a widely used treatment
option. Initial cohort studies1–4 suggested that the use
of a stent was associated with lower mortality, morbidity
and colostomy rates than emergency surgical interven-
tion. Randomized trials thereafter showed conflicting
results, and meta-analyses5 did not confirm a reduction in
mortality or secondary stoma rate.
The Dutch Stent-In 2 randomized clinical trial
(ISRCTN46462267) compared stenting as a bridge to
surgery with emergency surgery. One of the poten-
tial complications of endoscopic stent placement in
this trial was tumour perforation. The clinical stent-
or procedure-related perforation rate was 13 per cent
(6 of 47), and occult perforations were revealed in a further
10 per cent of the resected specimens (3 of 31)6.
The possibility of tumour cell dissemination result-
ing from stent insertion and/or tumour perforations is
worrying, and potential oncological consequences have
been debated extensively7. Moreover, interest in potential
tumour reactivity to stent placement is increasing8. In the
present update of the Stent-In 2 trial, the impact of colonic
stent placement as a bridge to elective surgery was assessed
for oncological outcome in patients presenting with malig-
nant colorectal obstruction.
Methods
Patients were identified from the database of the Stent-In
2 trial9. The trial was stopped prematurely in March 2010
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in accordance with advice from the Data Safety Monitor-
ing Board. Interim analysis of the first 60 included patients,
and thereafter the first 90 patients, revealed an increased
risk of 30-day morbidity (relative risk 1⋅60 (95 per cent c.i.
0⋅85 to 3⋅01) and 1⋅62 (0⋅94 to 2⋅78) respectively) for the
stent group compared with the emergency surgery group.
In addition, interim analysis recorded no difference in the
primary outcome of the study, which was global health sta-
tus. Details of the study design and short-term outcomes
have been published previously6. Patients randomized to
emergency surgery underwent resection of the primary
tumour, with either primary anastomosis, temporary stoma
or definitive stoma, at the discretion of the surgeon. Those
randomized to stent placement received either an enteral
Wallstent™ (diameter 22 mm; Boston Scientific, Marlbor-
ough, Massachusetts, USA) or a WallFlex™ colonic stent
(diameter 25 mm; Boston Scientific).
Patients with non-malignant obstruction, those in whom
malignancy was not confirmed histopathologically and
patients who were eventually treated with palliative intent
were excluded from the present study. The decision
regarding intentionally palliative or curative treatment was
made during multidisciplinary team meetings. Patients
with resectable liver metastasis were treated with curative
intent.
Follow-up and data collection
In the Dutch Stent-In 2 trial, patients were initially
followed for at least 6 months after randomization.
Prospectively collected patient demographics, treatment
characteristics and pathology reports were complemented
retrospectively with data on adjuvant treatment, recurrence
(locoregional recurrence or distant metastasis) and survival.
Information was obtained from hospital medical records
and general practitioners. The total follow-up was calcu-
lated from the date of randomization in the Stent-In 2 trial.
Endpoints
Endpoints of the study were overall and loco-
regional disease recurrence, disease-free survival (DFS),
disease-specific survival (DSS) and overall survival after
4 years. Diagnosis of disease recurrence was based on radi-
ological imaging or histopathological investigation. Loco-
regional recurrence was defined as intestinal, regional
lymph node or peritoneal recurrence. DFS was defined as
the time between resection of the primary tumour and the
diagnosis of disease recurrence or death from any cause.
DSS was defined as the time to cancer-specific death, and
overall survival was defined as the time to death from any
cause.
Statistical analysis
Data were analysed based on the on-treatment principle10.
Continuous data are presented as median (i.q.r.) and were
compared using the Mann–Whitney U test. For dichoto-
mous outcomes, the stent and emergency surgery groups
were compared by means of χ2 or Fisher’s exact test. The
Kaplan–Meier method was used for survival analysis, with
comparison between stent and emergency surgery groups
using the log rank test. In addition, a subanalysis was per-
formed of all patients who had a stent-related perfora-
tion within the stent group. Inclusion in this subgroup was
based on the presence of tumour perforation on patholog-
ical examination; this included both clinical and subclini-
cal perforations. Estimated survival rates are reported with









Age (years)* 70 (61–79) 67 (60–67) 0⋅839§
Sex ratio (M : F) 18 : 14 12 : 14 0⋅598¶
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Lymph node count* 13 (7–19) 15 (12–19) 0⋅180§
Positive lymph node count* 2 (1–8) 3 (1–7) 0⋅508§
Radical resection 31 26 1⋅000
Adjuvant chemotherapy 15 13 1⋅000¶
Follow-up (months)* 45 (35–60) 41 (19–55) 0⋅373§
*Values are median (i.q.r.). †Insufficient deployment of inserted stent (1),
inability to insert guidewire (3), suspicion of guidewire-induced
perforation (2). ASA, American Society of Anesthesiologists. ‡Fisher’s
exact test, except §Mann–Whitney U test and ¶χ2 test.
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Fig. 1 Kaplan–Meier survival curves for patients randomized to emergency surgery or colonic stenting: a disease-free survival,
b disease-specific survival and c overall survival. a P = 0⋅149, b P = 0⋅061 and c P = 0⋅468 (log rank test)
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95 per cent c.i.11. All tests were two-sided and P < 0⋅050
indicated statistical significance. Statistical analyses were
performed with SPSS® for Windows® version 19.0 (IBM,
Armonk, New York, USA).
Results
A total of 98 patients were included in the original Stent-In
2 trial between 2007 and 20096. Thirty-nine patients were
excluded from the present analysis because of benign dis-
ease (16) or palliative treatment (7 in whom the primary
tumour was never resected, 9 with unresectable liver metas-
tases, 4 with incurable peritoneal metastases, and 3 with
distant metastases at multiple sites). One additional patient
had withdrawn from the trial and was not included in the
analysis. Characteristics of the 58 remaining patients are
summarized in Table 1.
Six patients randomized to receive a stent as a bridge to
surgery underwent emergency operation. In one of these
patients the stent did not deploy well enough to result
in clinical decompression. The guidewire could not be
positioned in the lumen of the tumour, resulting in a false
route in three patients and guidewire-induced perforation
in two.
Stent-related perforations occurred in six of 26 patients in
the stent group. Three stent-related perforations presented
clinically (including 2 after complicated stent placement
procedures) and a further three became apparent during
pathological examination.
Recurrence and survival
Median follow-up was 45 (35–60) and 41 (19–55) months
in the emergency surgery and stent groups respectively.
Three of the 58 patients were lost to follow-up after 6–11
months.
A recurrence developed in nine of 32 patients after emer-
gency surgery (2 locoregional recurrence, 7 distant metas-
tasis) and in 13 of 26 patients after stent placement (5
locoregional metastasis, 8 distant metastasis).
The estimated 4-year DFS was 49 (95 per cent c.i. 32
to 67) and 30 (10 to 51) per cent in the emergency surgery
and stent groups respectively (Fig. 1a). Four-year DSS rates
were 87 (73 to 100) and 66 (37 to 95) per cent respectively
(Fig. 1b), and overall survival rates were 67 (50 to 84) and
58 (38 to 78) per cent (Fig. 1c).
For the subgroup analysis of stent-related perforations,
endpoints were calculated separately for patients with (6)
and without (20) stent-related perforation (Table 2).
Five of six patients developed a recurrence after a
stent-related perforation (3 locoregional recurrence, 2 dis-
tant metastasis) compared with eight of 20 patients without









Age (years)* 66 (58–79) 81 (69–85) 0⋅046‡
Sex ratio (M : F) 10 : 10 2 : 4 0⋅652















Lymph node count* 15 (10–20) 14 (12–17) 0⋅836‡
Positive lymph node count* 3 (1–7) 2 (1–7) 0⋅539‡
Adjuvant chemotherapy 11 2 0⋅645
Follow-up (months)* 43 (22–54) 29 (12–57) 0⋅533‡
*Values are median (i.q.r.). ASA, American Society of Anesthesiologists.
†Fisher’s exact test, except ‡Mann–Whitney U test.
stent-related perforation (2 locoregional metastasis, 6
distant metastasis).
The 4-year DFS rate was 0 (0 to 0) per cent in patients
with a stent-related perforation, and was worse than
the rate of 45 (22 to 68) per cent in patients without
stent-related perforation (Fig. 2a). DSS rates were 60 (17
to 100) and 69 (46 to 92) per cent respectively (Fig. 2b).
The overall survival rate was 50 (10 to 90) per cent for
patients with a stent-related perforation and 62 (39 to 84)
per cent among those without perforation (Fig. 2c).
Discussion
The results of this study are in line with data underlining
concerns about potential negative oncological outcomes
of colonic stent placement8,12–14. Examination of resected
stented specimens showed that tumour and peritumoral
ulceration occurred more frequently as a result of stents15.
In addition, tumour manipulation during guidewire inser-
tion, dilatation and stent deployment can cause disrup-
tion with potential spread of cancer cells (or their shed
particles)7. Only two of the six patients with stent-related
perforation in the present study received adjuvant systemic
chemotherapy. Although it is unknown whether adjuvant
systemic chemotherapy is able to prevent outgrowth of
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a  Disease-free survival
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Fig. 2 Kaplan–Meier survival curves for patients in the emergency surgery group and those who had colonic stenting with or without
perforation: a disease-free survival, b disease-specific survival and c overall survival. a P = 0⋅007, b P = 0⋅099 and c P = 0⋅478 (log rank
test)
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direct tumour spread after perforation, this may have influ-
enced the overall recurrence rate16.
Literature on the oncological consequences of colonic
stent placement in the curative setting is scarce. Recently,
cohort studies have compared the oncological outcome of
stenting as a bridge to surgery with emergency surgery.
The group from St Vincent’s University Hospital in
Dublin12 showed similar overall and cancer-specific sur-
vival in 49 patients. This has been echoed by others17,
but there have also been reports of a negative impact on
cancer outcomes. One retrospective study8 used a propen-
sity score to adjust for allocation bias in 48 patients who
received a bridging stent and 39 who underwent emergency
surgery. The 5-year overall survival rate was significantly
lower in the stent group than in the emergency surgery
group (25 versus 62 per cent respectively) and the 5-year
cancer specific mortality rate was significantly higher in
the stent group (48 versus 21 per cent). Finally, in another
study14 of patients aged 75 years or younger, 38 of whom
were stented and 24 had emergency surgery, the local
recurrence-free survival rate was significantly worse after
stenting (8 versus 32 per cent; P = 0⋅038).
The prevalence of stent-related complications is likely
to be underestimated, because subclinical perforations
may be identified only at the time of pathological
examination18–20. The prevalence of clinical stent-related
perforation is 6⋅9 per cent based on meta-analysis5. The
risk of perforation may be related to local anatomy, tumour
factors (length and constitution), stent design and expe-
rience of the clinician placing the stent1,18,21–23. Because
it is still not clear how stent-related perforations can be
prevented, this risk should be given serious consideration
in clinical decision-making. Even if stent placement seems
to be uncomplicated clinically, tumour biology may be
altered owing to the mechanical stress, and tumour spillage
may occur because of tumour disruption. A Markov chain
Monte Carlo decision analysis model determined differ-
ences in effectiveness and costs between the two strategies
for different patient scenarios based on perioperative risk
factors24. Probabilities of outcome variables were based on
systematic review of 54 studies including 1198 patients.
Based on this analysis, the authors concluded that the ben-
efits of colonic stenting are modest in low-risk patients,
and may not outweigh the risks. Therefore, emergency
surgery is probably the preferred treatment strategy for
patients without significantly increased operative risk.
On the other hand, stenting is probably the preferred
strategy in patients at increased operative risk (age above
70 years, American Society of Anesthesiologists fitness
grade III or more). The potentially impaired oncological
outcome related to the risk of stent-related perforation
seems to become less important than the increased risk of
postoperative death in these frail patients.
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